Cancer Research Versailles No Abst  Frontiers in Basic Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Li, Q.
Right arrow Articles by Chang, A. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Li, Q.
Right arrow Articles by Chang, A. E.
[Cancer Research 65, 1063-1070, February 1, 2005]
© 2005 American Association for Cancer Research


Immunology

Synergistic Effects of IL-12 and IL-18 in Skewing Tumor-Reactive T-Cell Responses Towards a Type 1 Pattern

Qiao Li1, Abbey L. Carr1, Elizabeth J. Donald1, Joseph J. Skitzki1, Ryugi Okuyama1, Lloyd M. Stoolman2 and Alfred E. Chang1

Departments of 1 Surgery and 2 Pathology, University of Michigan Medical Center, Ann Arbor, Michigan

Requests for reprints: Qiao Li, Division of Surgical Oncology, Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI 48109-0932. Phone: 734-936-4392; Fax: 734-647-9647; E-mail: qiaoli{at}umich.edu.

We have previously described the antitumor reactivity of tumor-draining lymph node (TDLN) cells after secondary activation with antibodies. In this report, we examined the effects of interleukin (IL)-12 and IL-18 on modulating the immune function of antibody-activated murine TDLN cells. TDLN cells were activated with anti-CD3/anti-CD28 monoclonal antibody followed by stimulation with IL-12 and/or IL-18. IL-18 in combination with IL-12 showed a synergistic effect in augmenting IFN{gamma} and granulocyte macrophage colony-stimulating factor secretion, whereas IL-18 alone had minimal effect. Concurrently, IL-18 prevented IL-12–stimulated TDLN cells from producing IL-10. The IL-12/IL-18–cultured TDLN cells therefore manifested cytokine responses skewed towards a Th1/Tc1 pattern. IL-12 and IL-18 stimulated CD4+ TDLN cells and enhanced IFN{gamma} production by CD4+ cells to a greater extent than by CD8+ cells. Use of NF-{kappa}B p50–/– TDLN cells suggested the involvement of NF-{kappa}B in the IL-12/IL-18 polarization effect. Furthermore, a specific NF-{kappa}B inhibitor significantly suppressed IL-12/IL-18–induced IFN{gamma} secretion, thus confirming the requirement for NF-{kappa}B activation in IL-12/IL-18 signaling. In adoptive immunotherapy, IL-12– and IL-18–cultured TDLN cells infiltrated pulmonary tumor nodules and eradicated established tumor metastases more efficiently than T cells generated with IL-12 or IL-18 alone. Antibody depletion revealed that both CD4+ and CD8+ cells were involved in the tumor rejection induced by IL-12/IL-18–cultured TDLN cells. These studies indicate that IL-12 and IL-18 can be used to generate potent CD4+ and CD8+ antitumor effector cells by synergistically polarizing antibody-activated TDLN cells towards a Th1 and Tc1 phenotype.

Key Words: IL-12 • IL-18 • T cells • NF-{kappa}B • Adoptive immunotherapy




This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
A. Khatri, Y. Husaini, K. Ow, J. Chapman, and P. J. Russell
Cytosine Deaminase-Uracil Phosphoribosyltransferase and Interleukin (IL)-12 and IL-18: A Multimodal Anticancer Interface Marked by Specific Modulation in Serum Cytokines
Clin. Cancer Res., April 1, 2009; 15(7): 2323 - 2334.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Gastrointest. Liver Physiol.Home page
D. Laubitz, C. B. Larmonier, A. Bai, M. T. Midura-Kiela, M. A. Lipko, R. D. Thurston, P. R. Kiela, and F. K. Ghishan
Colonic gene expression profile in NHE3-deficient mice: evidence for spontaneous distal colitis
Am J Physiol Gastrointest Liver Physiol, July 1, 2008; 295(1): G63 - G77.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. N. MacGregor, Q. Li, A. E. Chang, T. M. Braun, D. P.M. Hughes, and K. T. McDonagh
Ex vivo Culture with Interleukin (IL)-12 Improves CD8+ T-Cell Adoptive Immunotherapy for Murine Leukemia Independent of IL-18 or IFN-{gamma} but Requires Perforin.
Cancer Res., May 1, 2006; 66(9): 4913 - 4921.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2005 by the American Association for Cancer Research.